This site is intended for healthcare professionals
Journals
  • Home
  • /
  • Journals
  • /
  • Coronary atherosclerosis
  • /
  • Treating obesity in patients with cardiovascular d...
Journal

Treating obesity in patients with cardiovascular disease: the pharmacotherapeutic options.

Read time: 1 mins
Published:31st Mar 2019
Author: Andrew CA, Saunders KH, Shukla AP, Aronne LJ.
Availability: Pay for access, or by subscription
Ref.:Expert Opin Pharmacother. 2019;20(5):585-593.
DOI:10.1080/14656566.2018.1561867

Introduction: Obesity is a growing health problem that has numerous comorbidities, including cardiovascular disease (CVD). The multi-disciplinary treatment of obesity now includes the use of pharmacotherapy. When treating patients with obesity and CVD, certain medications may be more appropriate than others.

Areas covered: Herein, the authors review the most commonly used FDA approved medications for the treatment of obesity, describing their mechanism of action, and the efficacy and safety of the medications as seen in recent studies, particularly in patients with CVD.

Expert opinion: In the population of patients with obesity and CVD, the medications orlistat, lorcaserin and liraglutide are considered the most appropriate options for their treatment, in terms of safety. Sympathomimetic medications, such as phentermine, should be avoided in this group. The recent CAMELLIA-TIMI 61 trial supports the safety of lorcaserin in patients with CVD. Until there are more studies, it is reasonable to extrapolate the findings of the LEADER trial, which found improved CV outcomes in subjects with type 2 diabetes taking liraglutide, to the population of nondiabetic patients being treated for obesity. Further cardiovascular outcomes trials (CVOT) are needed to assess the safety of other pharmacotherapeutic options for weight loss.

 

Read abstract on library site

Access full article